心脏骤停精准医疗:ICECAP(PRECICECAP)研究方案与信息学方法
PRECICECAP是一项基于ICECAP试验的研究,ICECAP为反应适应性剂量探索试验,测试不同时长的治疗性低温。12个ICECAP站点将收集院外心脏骤停后常规使用的多模态数据,包括病例报告表、详细用药数据、心肺和脑电波形以及DICOM文件。研究将与Moberg Analytics合作开发免费软件平台,使用自编码器神经网络创建所有原始波形和衍生特征的低维表示,并在复温时删失以确保临床可用性,以指导低温最佳时长。最终将创建监督深度学习神经网络算法,从大量新特征中直接预测90天功能结局。研究结论指出,心脏骤停是异质性疾病,PRECICECAP将推进基于个体需求与治疗反应性稳健指标的个体化神经重症监护。
要点
- PRECICECAP研究正在入组,将于2025年末完成,旨在用机器学习发现预测治疗性低温最佳时长和90天功能结局的新生物标志物特征。
- ICECAP是一项反应适应性、剂量探索试验,测试不同时长的治疗性低温,12个ICECAP站点参与PRECICECAP数据收集。
- 数据来源包括ICECAP病例报告表、详细用药数据、心肺和脑电波形以及DICOM文件。
- 将使用自编码器神经网络创建原始波形和衍生特征的低维表示,在复温时删失以确保临床可用性。
- 将创建监督深度学习神经网络算法,从大量新特征中直接预测90天功能结局。
适用人群与场景
- 院外心脏骤停后复苏成功并接受治疗性低温的患者,来自12个ICECAP站点。
处置流程与药物剂量
- 测试不同时长的治疗性低温,具体时长未在摘要中列出。
研究设计与关键结果
- 研究类型:基于ICECAP试验的研究方案与信息学方法,ICECAP为反应适应性剂量探索试验。
- 样本量:摘要未报告样本量。
- 中心数:12个ICECAP站点。
- 干预与对照:比较不同时长的治疗性低温。
- 主要终点:发现预测治疗性低温最佳时长和90天功能结局的新型生物标志物特征。
- 数据来源:ICECAP病例报告表、详细用药数据、心肺和脑电波形、DICOM文件。
- 分析方法:使用自编码器神经网络创建原始波形和衍生特征的低维表示,在复温时删失;并考虑历史上认为重要的简单特征;最后创建监督深度学习神经网络算法从大量新特征中直接预测90天功能结局。
- 当前状态:PRECICECAP正在入组,将于2025年末完成。
证据类型、等级与局限
- 研究方案与信息学方法描述,为基于ICECAP试验的研究计划,尚未报告结果数据。
- 局限:原文未报告局限性
对床旁实践的改变
- 原文未报告可用临床实践结果,未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Most trials in critical care have been neutral, in part because between-patient heterogeneity means not all patients respond identically to the same treatment. The Precision Care in Cardiac Arrest: Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (PRECICECAP) study will apply machine learning to high-resolution, multimodality data collected from patients resuscitated from out-of-hospital cardiac arrest. We aim to discover novel biomarker signatures to predict the optimal duration of therapeutic hypothermia and 90-day functional outcomes. In parallel, we are developing a freely available software platform for standardized curation of intensive care unit-acquired data for machine learning applications.
METHODS: The Influence of Cooling duration on Efficacy in Cardiac Arrest Patients (ICECAP) study is a response-adaptive, dose-finding trial testing different durations of therapeutic hypothermia. Twelve ICECAP sites will collect data for PRECICECAP from multiple modalities routinely used after out-of-hospital cardiac arrest, including ICECAP case report forms, detailed medication data, cardiopulmonary and electroencephalographic waveforms, and digital imaging and communications in medicine files (DICOMs). We partnered with Moberg Analytics to develop a freely available software platform to allow high-resolution critical care data to be used efficiently and effectively. We will use an autoencoder neural network to create low-dimensional representations of all raw waveforms and derivative features, censored at rewarming to ensure clinical usability to guide optimal duration of hypothermia. We will also consider simple features that are historically considered to be important. Finally, we will create a supervised deep learning neural network algorithm to directly predict 90-day functional outcome from large sets of novel features.
RESULTS: PRECICECAP is currently enrolling and will be completed in late 2025.
CONCLUSIONS: Cardiac arrest is a heterogeneous disease that causes substantial morbidity and mortality. PRECICECAP will advance the overarching goal of titrating personalized neurocritical care on the basis of robust measures of individual need and treatment responsiveness. The software platform we develop will be broadly applicable to hospital-based research after acute illness or injury.
参考来源
- Elmer J, He Z, May T, et al. Precision Care in Cardiac Arrest: ICECAP (PRECICECAP) Study Protocol and Informatics Approach. Neurocrit Care. 2022. PMID: 35229231. doi:10.1007/s12028-022-01464-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。